Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Pediatr Hematol Oncol. 2007 Sep;29(9):646-8.

Secondary acute myeloid leukemia after etoposide therapy for retinoblastoma.

Author information

  • 1Department of Pediatric Hematology-Oncology, Hadassah University Hospital, Jerusalem, Israel. michalew@hadassah.org.il

Erratum in

  • J Pediatr Hematol Oncol. 2007 Oct;29(10):728. Pèer, Jacob [corrected to Pe'er, Jacob].

Abstract

Retinoblastoma is the most common eye tumor in children and is highly curable. Patients with hereditary retinoblastoma, have an increased risk of developing additional tumors, predominantly sarcomas. Most chemotherapy regimens used in retinoblastoma include etoposide, an epipodophyllotoxin associated with a risk of secondary myeloid leukemia. The use of etoposide in patients with a cancer predisposition syndrome such as retinoblastoma is potentially harmful, however, reports of secondary acute myeloid leukemia in patients treated with etoposide for retinoblastoma are rare. We report a case of a patient who developed secondary acute myeloid leukemia after etoposide treatment for retinoblastoma.

PMID:
17805043
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk